Treatment options for recurrent glioblastoma: pitfalls and future trends (Q37483971)

20 August 2017

1 reference

title

Treatment options for recurrent glioblastoma: pitfalls and future trends (English)

1 reference

20 August 2017

1 reference

Enrico Franceschi

1

0 references

Alba A. Brandes

object named as

Alba A Brandes

6

0 references

author name string

Alicia Tosoni

2

1 reference

20 August 2017

Stefania Bartolini

3

1 reference

20 August 2017

Valeria Mazzocchi

4

1 reference

20 August 2017

Antonio Fioravanti

5

1 reference

20 August 2017

publication date

1 May 2009

1 reference

Expert Review of Anticancer Therapy

20 August 2017

published in

1 reference

20 August 2017

volume

9

1 reference

20 August 2017

issue

5

1 reference

20 August 2017

page(s)

613-619

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

20 August 2017

cites work

1 reference

Evaluation of malignant glioma patients during the postirradiation period

21 January 2018

1 reference

Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme

21 January 2018

1 reference

Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions?

21 January 2018

1 reference

Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis

21 January 2018

1 reference

Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery--in malignant glioma

21 January 2018

1 reference

Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas

21 January 2018

1 reference

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression

21 January 2018

1 reference

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

21 January 2018

1 reference

Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

21 January 2018

1 reference

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

21 January 2018

1 reference

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology

21 January 2018

1 reference

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

21 January 2018

1 reference

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

21 January 2018

1 reference

Reoperation for glioblastoma

21 January 2018

1 reference

Survival and functional status after resection of recurrent glioblastoma multiforme

21 January 2018

1 reference

Therapeutic options for recurrent high-grade glioma in adult patients: recent advances

21 January 2018

1 reference

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

21 January 2018

1 reference

Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma

21 January 2018

1 reference

The role of chemotherapy in recurrent malignant gliomas: an overview

21 January 2018

1 reference

Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

21 January 2018

1 reference

First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia

21 January 2018

1 reference

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study

21 January 2018

1 reference

Chemotherapy for adults with malignant glioma

21 January 2018

1 reference

Salvage temozolomide for prior temozolomide responders

21 January 2018

1 reference

A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma

21 January 2018

1 reference

Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience

21 January 2018

1 reference

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

21 January 2018

1 reference

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

21 January 2018

1 reference

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors

21 January 2018

1 reference

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

21 January 2018

1 reference

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

21 January 2018

1 reference

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

Colon perforation during antiangiogenic therapy for malignant glioma

21 January 2018

1 reference

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

21 January 2018

1 reference

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.09.23

1 reference

20 August 2017

1 reference